Good morning, everyone, and welcome to the TelyRx Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following the presentation, we will conduct a question and answer session. To join the question queue, you may press star then one on your telephone keypad. You will hear a tone acknowledging your request. If anyone has any difficulty hearing the conference, you may press star then zero for operator assistance at any time. Listeners are reminded that portions of today's discussion may contain forward-looking statements that reflect the company's current views with respect to future events. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. For more information on TelyRx's risks and uncertainties related to these forward-looking statements, please refer to the company's filing statement dated March 24, 2026, which is posted on SEDAR+. In addition, in today's discussion, we will refer to non-IFRS financial measures such as adjusted EBITDA that do not have any standardized meaning prescribed by IFRS. Management believes non-IFRS results are useful to enhance the understanding of the company's ongoing performance. These are supplemental to and should not be considered in isolation from or as a substitute for IFRS financial measures. These non-IFRS measures are defined in our earnings press release and available in our MD&A, which also includes a reconciliation of these measures to their respective most directly comparable IFRS financial measures. The company's press release, MD&A, and financial statements are available on its website and on SEDAR+. All figures presented on today's call are in U.S. Dollars unless otherwise stated. This morning's call is being recorded on the 10th of August 2026 at 8:30 A.M. Eastern Time. I would now like to turn the call over to Vanessa Slowey, President and Chief Executive Officer of TelyRx. Please go ahead, Ms. Slowey. Thank you. Good morning, everyone. Welcome to our second quarter 2026 earnings call. With me this morning is our Chief Financial Officer, John Cascio. TelyRx exists to make essential medication easy to get. No appointments, no waiting rooms, no unnecessary friction between the patient and the prescription they already know they need. That's our mission. This quarter reinforced why it matters to our customers. Millions of Americans live with everyday health needs, where the medication is routine, but the traditional system isn't. Our platform closes that gap. A patient goes online, selects from our formulary of FDA-approved medications, and a licensed provider in their state reviews the request. If approved, one of our licensed pharmacies fills and ships it directly to their door. No insurance, no travel, just the cost of the medication and a flat $22 visit fee. We're not competing at the margins of healthcare. We're replacing an outdated behavior with a better one. Our first-mover position in a cash pay market continues to compound. Repeat customers remain a significant driver of revenue, and our reach, now covering the vast majority of the U.S. population, keeps widening the moat between us and providers who only do telehealth or only do pharmacy, but not both. The cash pay prescription market remains large, under-penetrated, and growing, and the ongoing shifts in U.S. insurance are only accelerating patients' willingness to pay directly for fast, convenient care. We remain focused on executing against that opportunity, and this quarter's results reflect that discipline. In the second quarter of 2026, for the three-month period ended June 30th, 2026, TelyRx delivered strong top-line growth and a healthy momentum in the part of our business that matters most for the long term, our repeat customers. This was a quarter of deliberate investment. We put capital to work behind customer acquisition, a new brand, website, and the people and channels that will carry our growth into the second half of the year. Let me walk you through the numbers and where we invested. Revenue grew 143% to $22.7 million over the prior year quarter. It was up 17% over the first quarter of this year. In June, we also passed a major operating milestone. TelyRx surpassed one million prescriptions filled since inception. That is an important proof point for the model, not just because of the absolute number, but because it reflects the trust customers are placing in us for routine prescription care and the repeat behavior that supports long-term value. Adjusted EBITDA was a loss of $3.2 million in the quarter. That figure reflects an investment in growth, in acquiring customers, in building our new brand and website with substantially improved functionality, and in the team and channels that support scaling. These are investments in the durable, recurring revenue base that is the core of our business. The heart of the story is our repeat customers, the people who came back to us month after month. This cohort grew 13% over the quarter. The revenue they generate grew 23%. That repeat business now makes up close to 70% of our total revenue, up from about 2/3 at the start of the year. As new customers convert into this repeat cohort, their lifetime revenue keeps compounding. This is why we continue to invest in bringing new customers in the door. Customers are also spending a little more with us each time they order. In plain terms, more people are choosing to stay with TelyRx, and they trust us more with their everyday health needs. That is exactly the kind of dependable repeat revenue we're building this company around. Our spending this quarter reflects a deliberate set of priorities. We increased our marketing investment, both to bring in new customers and to reengage our existing base. That investment is showing up directly in the 20% growth in our repeat customers. We also began exploring new channels beyond our usual mix, which broadens our reach and reduces our dependence on any one channel over time. This kind of early-stage exploration carries higher costs by design, but it's how we build an asset that's difficult to replicate. With more than 500 products in our portfolio, there's no simple playbook for reaching the right customer at the right moment. Every channel we explore, every result we see sharpens our understanding in ways a new entrant to this business simply doesn't have access to. That accumulated expertise compounds and is a meaningful part of what keeps us ahead. Alongside that, we invested in our team and in building our new brands and website ahead of our second half. Our operating costs and the core economics of each order remained on plan. The most exciting part of what comes next is that we are giving TelyRx a fresh new look and a much better experience for our customers. Earlier in the third quarter, we launched a completely rebuilt website along with the refreshed brand. This is a really big deal for us. A cleaner website means a better experience and more efficient access, which will enable us to achieve lower cost to win each customer. Later this year, we plan to launch a new app designed to make it easier for our existing customers to reorder and stay with us, which strengthens exactly the repeat business I just described. We've been investing in this work throughout the quarter, and we expect it to start paying off in the second half of the year. Subsequent to quarter end, we announced a major expansion of our Clearwater, Florida headquarters and pharmacy operations, more than tripling our overall footprint. The rationale for this is straightforward. As consumer adoption increases, we need capacity that protects the service levels, rapid turnaround times, and order accuracy that customers expect from TelyRx. The larger Clearwater presence gives us room to scale pharmacy, clinical, and fulfillment roles, supports the growing demand without compromising the experience that drives repeat orders. We have the customers, we have the cash to get there, and now we're giving them a better TelyRx to come home to. I'm very proud of the entire TelyRx team, those in our pharmacies, and the people that work hard every day to improve customer experience. It's this dedication and hard work of the collective team that has enabled us to deliver these results, and this is just the beginning. I'm now going to turn the call over to John, who'll discuss our second quarter's financial results in more detail. John? Thank you, Vanessa, good morning, everyone. Revenue in the second quarter grew to $22.7 million compared to $9.3 million in the second quarter of 2025, an increase of $13.3 million or 143%. The year-over-year increase in revenue was driven primarily by growth in overall sales volumes and continued contributions from both recurring customers and new customer acquisition. Revenue consisted of revenue from recurring customers of $15.6 million in the quarter and revenue from new customers of $7.1 million. Second quarter gross profit increased to $13 million from $5.1 million in the second quarter of 2025, an increase of $7.9 million or 156%. Gross margin was 57% in the second quarter of this year, up from 54% in the same period a year ago. The increase in gross margin was primarily due to improved purchasing economics for prescription medications, including increased direct purchasing from manufacturers and more favorable pricing negotiated with wholesale suppliers. Gross margin also benefited from lower transaction costs from improved margins on shipping and handling. Adjusted EBITDA in the quarter was a loss of $3.2 million, compared to a loss of $900,000 in the second quarter of 2025. The loss in adjusted EBITDA was primarily driven by greater investments in marketing to drive new unique customers and retention, increased investments in headcount growth to support scaling, and a strategic investment in brand campaign and resulting new website that launched in July of 2026. Cash used in operations in the second quarter was $4.3 million, compared to cash used of $300,000 in the same period last year. Our free cash flow in the second quarter of 2026 was a loss of $4.9 million, compared to a loss of $750,000 in Q2 2025. With regard to prescription volumes, we saw record prescriptions filled in June of this year of 90,000, while filling 257,000 prescriptions in the quarter, compared to 114,000 in Q2 2025, an increase of 125%. Turning to our balance sheet, as at June 30th, 2026, we had cash and cash equivalents of $21.7 million, compared with $27 million at March 31st, 2026. We have meaningful operating leverage across a number of areas, and the business can scale significantly with limited additional investment. CapEx spend of $800,000 for the six months ended is modest, given the investment that we've already made to date and given the nature of operating leverage in the business. Overall, our financial position remains very strong, and we believe we are well positioned to support continued growth while maintaining a conservative leverage profile. With that, I'll turn the call back over to Vanessa. Thanks, John. Our operating discipline is grounded in our healthcare industry roots, rigorous compliance, clinical integrity, and a platform patients trust. A carefully selected formulary, which now includes more than 500 medications, a nationwide network of licensed providers, and a seamless digital experience is our foundation, and it has not changed. Everyone needs medication at some point, and TelyRx has made getting it remarkably simple. That simplicity is why patients keep returning to us. It's a level of convenience they haven't found anywhere else, and the opportunity in front of us is real, and it's growing. Our growth engine continues to deliver, and our repeat customer base remains the majority of our revenue. Our infrastructure, which is our provider network and our pharmacy footprint, is built for volume well beyond where we are today. Cash pay prescriptions remain one of the fastest growing corners of U.S. healthcare, we intend to keep expanding access to affordable, high quality care as we scale. Thank you for being part of this with us. I'm going to hand you now back to the operator to questions. Thank you. Ladies and gentlemen, we will now begin the question- and- answer session. To join the question queue, you may press star then one on your telephone keypad. You will hear a tone acknowledging your request. If you're using a speakerphone, please pick up your handset before pressing any keys. If you wish to remove yourself from the question queue, you may press star then two. The first question comes from Kenric Tyghe with Canaccord Genuity. Your line is open. Thank you, good morning. Congrats on the rebrand and the improved functionality. Definitely a step change to an outside observer. If I could, just with respect to my first question here, in terms of marketing spend, how is the decision you made to bring it in-house tracking relative to your expectations? Second to that, how are you navigating the CPM rate increases by the leading platforms year to date? Thanks, Kenric. Okay. Well, bringing marketing in-house is tracking to expectations. The point of it probably has to be, well, first of all, three things. One was our first 30-day data, our testing cadence, and our own channels like email, SMS, and the patient base. That's exactly what let us restructure paid search and test new channels this quarter. It carries some near term learning costs by design. It's building an asset a new entrant can't shortcut, because with 400+ products, there's no off-the-shelf playbook for reaching the right patient at the right moment. The payoff is a lower blended cost to acquire over time as owned and organic channels grow. We're roughly at 5% organic today and targeting at 35%-40% over the medium term. Going on to your question on the platform CPMs. We're structurally reducing our exposure to them because platform CPMs have been rising across the industry, as you know, our response is structural. It's not reactive. There's four things here. Number one, we diversify beyond any single platform, we can route spend to the best returning inventory. Our new website went live in July. It lifts conversions, which lowers effective CAC even when the CPMs climb. We're shifting mix towards owned and organic channels that are insulated from platform inflation. We're managing to an LTV CAC guardrail around 4.5 x payback under 12 months. We spend to the ratio, and if platforms get expensive, the dollars move. That's some great color. Thank you, Vanessa. Just with respect to spend and the build out, obviously SG&A coming in perhaps a little higher than people had expected coming into the print. Could you speak to where you are on that step up and how you're thinking about the glide path on SG&A margins in the second half of the year? Thanks, Kenric. Good question. I'll paint some additional color on our operating expenses. We did see SG&A increase throughout the quarter, that was largely intentional as we continue to invest ahead of our growth of the business. There's really three primary areas where we invested, one being digital marketing, where we continue to see attractive opportunities to acquire new customers. Second is our headcount growth, as we build out the operational infrastructure needed to support a significantly larger and growing business. As you pointed out, Kenric, we're excited that we invested in our new brand and digital experience, including the development and enhancement of our website, which again went live this July. As we look to the second half of this year, we believe much of that foundational investment is now in place. We're going to continue to invest where we see attractive returns, particularly in customer acquisition, we do not expect SG&A to grow at the same rate as revenue. As we move through the back half of this year, we expect to begin seeing greater operating leverage, and SG&A as a percentage of revenue gradually improve as we scale. That's great. Thanks, John. Just a quick final one for me, and recognizing it's a little bit of a left field question. There have been a lot of peptide related headlines recently. Recognizing that compounding is not in your wheelhouse, is there a scenario, though, where sort of the broader peptide market could become an interesting opportunity down the line? Yeah, it's a fair question. We're watching it closely, right? We've looked at it, and we've made a deliberate decision to stay focused. Let's start with what we are. TelyRx isn't a telehealth front end of hand the patient off. We're a licensed pharmacy, and that carries a real duty around the quality and safety of what we're dispensing. We're really focused on what's already working for us. FDA approved everyday medications that our patients need on a repeat basis, and a licensed pharmacy on the quality and safety of everything we dispense. Where the opportunity in front of us is, and it's a big one, that is it. If an approved peptide therapy fits our model down the road, then we'd look at it through the same lens as anything else that we add right now. Right now our attention is on executing on the core business, Kenric. Fantastic. Thank you for that. I'll get back in queue. Thanks. Thank you. Once again, if you have a question, please press star then one. The next question comes from Ben Atkins, private investor. Please go ahead. I was wondering if you have any analysis, even though the new website has been up just a short period of time, of how much higher you're converting at. Thank you. Okay. Thanks, Ben. The new site went live in July, and we're only a few weeks in, so it's far too early to draw any long-term conclusions. I'd caution against reading too much into a small window like that. That said, the early read is encouraging. The site's cleaner and simpler, and it was built specifically to improve the customer experience and conversion. We'll let the data mature over the coming quarters before we put any firm numbers around it. So far, we like what we're seeing, and it's reinforcing why we made the investment. Thank you. Thank you. This concludes the question- and- answer session. I would like to turn the conference back over to Vanessa Slowey for any closing remarks. Thank you everyone for participating in today's call and indeed for your continued interest in TelyRx. We look forward to reporting on our continued progress next quarter. This brings to a close today's conference call. You may disconnect your lines. Thank you for participating and have a pleasant day.